Eli Lilly's next-generation obesity drug, retatrutide, achieved significant weight loss in a late-stage trial, with patients losing up to 28.3% of their body weight over 80 weeks. The drug, which targets three gut hormones, outperformed existing treatments and showed promise for patients with high BMI at risk of cardiovascular issues. Side effects were mostly gastrointestinal but manageable, and a lower dose showed good tolerability. Lilly plans to seek approval soon, aiming to strengthen its position in the growing obesity and diabetes drug market against competitors like Novo Nordisk.
Incyte has signed a $120 million partnership with Genesis Molecular AI, including $80 million upfront and a $40 million equity investment, to advance AI-driven drug discovery. This deal could exceed $1 billion with future milestones and royalties, us...
Eli Lilly has filed a civil lawsuit alleging a $200 million rebate fraud scheme involving several bishops of the Church of God in Christ and a Florida mail-order pharmacy, DrugPlace. The scheme involved false claims for rebates on the diabetes drug T...
The iShares U.S. Pharmaceuticals ETF (IHE) has gained 38% over the past year despite threats from U.S. drug pricing policies like the 'most favored nation' order. The ETF benefits from dividends and strong drug pipelines, especially from major holdin...
The Fidelity MSCI Health Care Index ETF (FHLC) has declined about 5% year-to-date, while the S&P 500 has risen 7%, and over five years FHLC returned 15% versus 80% for the S&P 500. FHLC tracks a broad healthcare index with 342 holdings but is heavily...
Eli Lilly demonstrates strong bullish technical indicators including price action, momentum, and relative strength, supporting a continued uptrend. Despite receiving an 'F' valuation grade, the company's growth, profitability, and upward earnings rev...
